Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.12 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.46 million versus the consensus estimate of $77.34 million.

2017 Financial Guidance

• Ironwood expects 2017 R&D expenses to be in the range of $145 million to $160 million.
• Ironwood expects 2017 SG&A expenses to be in the range of $235 million to $250 million.
• Ironwood expects the combined Allergan and Ironwood total 2017 marketing and sales expenses for LINZESS to be in the range of $250 million to $280 million.
• Ironwood expects 2017 net interest expense to be approximately $40 million.
• Ironwood expects to use less than $100 million in cash for operations in 2017.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.